Cerevel gets Phase III Parkinson’s win on heels of $8.7B AbbVie acquisition
Cerevel Therapeutics reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.